Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare once a week and once every other week darbepoetin
alfa on the change in hemoglobin levels between the screening/baseline period and the
evaluation period (weeks 25-30). This study will also assess the change in mean hemoglobin
over 4 week intervals, instability of hemoglobin concentrations, darbepoetin alfa dosing
requirements and red blood cell transfusions.